公开(公告)号：US11897968B2

公开(公告)日：2024-02-13

申请号：US17118921

申请日：2020-12-11

Applicant: Alector LLC

Inventor： Seung-Joo Lee ,  Spencer Liang ,  Angie Yee ,  Marina Roell ,  Arnon Rosenthal

IPC: C07K16/40 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/507 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/76

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MerTK polypeptide, e.g., a mammalian MerTK or human MerTK, and use of such compositions in treating an individual in need thereof.

公开(公告)号：US12215149B2

公开(公告)日：2025-02-04

申请号：US17722624

申请日：2022-04-18

Applicant: Alector LLC

Inventor： Philip Kong ,  Herve Rhinn ,  Tina Schwabe ,  Angie Yee ,  Arnon Rosenthal

IPC: C07K16/18 ,  A61K39/00 ,  A61P25/28 ,  C07K16/28

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A6A polypeptide, e g., a mammalian MS4A6A or human MS4A6A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US11472874B2

公开(公告)日：2022-10-18

申请号：US16965676

申请日：2019-01-31

Applicant: Alector LLC

Inventor： Philip Kong ,  Herve Rhinn ,  Tina Schwabe ,  Angie Yee ,  Ilaria Tassi ,  Muhammad Abbas Alhawagri ,  Arnon Rosenthal

IPC: C07K16/28

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US11440957B2

公开(公告)日：2022-09-13

申请号：US16959081

申请日：2018-12-21

Applicant: ALECTOR LLC

Inventor： Arnon Rosenthal ,  Eric Brown ,  Tina Schwabe ,  Angie Yee ,  Herve Rhinn

IPC: C07K16/18 ,  C07K16/28

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.